[1] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[2] |
CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun.
Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
|
[3] |
LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana.
Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.
|
[4] |
CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou.
Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
|
[5] |
SUN Yixin, WANG Chen, YU Yuelin, GUO Peng, NIE Xiaolu.
Safety Surveillance for Vaccine-Induced Immune Thrombotic Thrombocytopenia: a Systematic Review
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 29-36.
|
[6] |
LIU Nannan, XI Yalin, CHEN Zhe.
One Case of Adrenocortical Insufficiency Caused by Cadonilimab
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 109-112.
|
[7] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[8] |
ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang.
Detection and analysis of signals of adverse events induced by deferasirox based on FAERS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
|
[9] |
XIA Lanfang, LI Keli, WANG Lei, LI Yan, WANG Huaqing.
Impact of comparator selection on signal detection in adverse events following immunization in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 798-804.
|
[10] |
WU Yi, HE Jinyang, WANG Xiaojian, ZhOU Xiaozhu, LIU Ranjia, GUO Mingxing, ZHAO Ying, DAI Wendi, CUI Xiangli.
Adverse events of COVID-19 vaccination in recipients of liver and kidney transplant based on US VAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 572-579.
|
[11] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|
[12] |
LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong.
Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
|
[13] |
YOU Xiaoyan, ZHENG Yingying, WANG Xianying.
Data-mining and analysis of adverse events signals for infliximab based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 335-340.
|
[14] |
WU Tingxi, ZHAO Zhigang, SHI Yanfeng, ZHANG Yang, ZHANG Yinan, ZHU Bin.
Risk assessment of colchicine-associated neurological adverse events based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 341-345.
|
[15] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|